The impact of plasma zinc status on the severity of prostate cancer disease

Victor C. Wakwe, Ehimen. P. Odum, Collins Amadi
Department of Chemical Pathology, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria

Purpose: The severity of prostate cancer (PCa), which determines the disease progression, is theorized to be a function of zinc status. Hence, this study was structured to determine the impact of zinc status on the severity and progression of PCa disease.

Materials and Methods: This was a descriptive cross-sectional study of 220 histologically-confirmed PCa patients and 220 age-matched controls, conducted prospectively in a Nigerian tertiary hospital. Plasma zinc, prostate-specific antigen, creatinine, fasting glucose, and estimated glomerular filtration rate were determined for both study groups. The International Society of Urological Pathology (ISUP) grades and the American Joint Committee on Cancer clinical staging were employed as indices for PCa severity (grade) and progression (stage) respectively.

Results: The PCa patients had markedly reduced plasma zinc status compared to controls (cases: 9.42±3.02 µmol/L versus controls: 15.23±4.47 µmol/L; p<0.001). Low zinc status was more pronounced within the severe grade and advanced PCa disease subgroups (p<0.001). Inverse relationships existed between zinc status and ISUP grades among the entire PCa patient (p<0.001) and the categorized PCa grade and stage subgroups (p<0.001). Low zinc status had significant impact of predicting severe (crude=odds ratio [OR], 8.714; p<0.001; age-adjusted=OR, 11.152; p<0.001) and advanced (crude=OR, 17.160; p<0.001; age-adjusted=OR, 18.927; p<0.001) PCa disease.

Conclusions: This study suggests that low plasma zinc status is associated with severe grade and advanced PCa disease. However, further well-designed studies with large sample sizes are warranted to confirm these associations.

Keywords: Neoplasm grading; Neoplasm staging; Prostatic neoplasms; Zinc

INTRODUCTION

The incidence and mortality of prostate cancer (PCa) disease around the globe has assumed an epidemic proportion especially among men of the black race [1]. The disease was relatively rare among Nigerian men during the 1960s but has risen exponentially to the number one position of all the male cancers in Nigeria according to a recent report [2]. The World Health Organization had reported a 4.0% prevalence rate of the disease among males within the developing countries [3]. However, a prevalence rate as high as 15.7% of the disease was documented recently in a population-based study reported from the Eastern part of Nigeria [4]. There are also various reports suggestive that the PCa disease is occurring among the younger Nigerian males in contrast to previous reports [5].
The majority of the PCa disease within the black race are of the severe grade with high International Society of Urological Pathology (ISUP) grades which are usually aggressive and characterized by high metastatic and advanced stage disease potential [6]. The ISUP grading system is an objective system employed to grade PCa disease during histologic examination of prostate tissues [6,7]. The scores define the degree of how the cancerous tissues resemble the normal tissues which determines the disease severity. The ISUP grades are based on the Gleason grading system [6,7]. A higher ISUP grade suggests poorly differentiated cancer tissues which exhibit severe and advanced stage biologic behaviors [6,7]. Hence, the severity of PCa is characterized by its grades which determines the disease stage, whereas the stage defines the progressive potential of the disease.

Evidence suggests that environmental factors acting in concert with genetic influences could be responsible for PCa severity which usually determines the disease progression [8-12]. Low zinc status is one environmental factor that has been implicated to play a role in prostate carcinogenesis and its severe variants which define the disease progression [11,12]. Zinc accumulates in the prostate ten times more than in any other human tissue where it maintains normal prostate health and inhibition of prostate carcinogenesis and progression via the reduction of energy needed for malignant transformation and the inhibition of metastatic potentials and advanced disease [13,14]. Zinc accumulation in the prostate is dependent on its extracellular concentrations [14]. Therefore, plasma zinc status is suggested to be a surrogate measure of its intra-prostatic concentration [15].

Report indicates that low plasma zinc status culminates in the reduction of intra-prostatic zinc levels which promotes prostate carcinogenesis and its various adverse clinicopathologic outcomes (grade and stage) [11,12]. However, most of these studies had emanated from western populations with a dearth of data in our region. Besides, very few of these studies had investigated the relationship between zinc status and PCa severity (grade) and progression (stage).

Hence, this study had been designed to examine the impact of low zinc status on the severity and progression of PCa disease using the ISUP grades and clinical staging as indices for severity and progression respectively.

**MATERIALS AND METHODS**

1. **Study location**

   The study was conducted in the Departments of Chemical Pathology, Histopathology, and Urology of the University of Port Harcourt Teaching Hospital (UPTH). The hospital is one of the tertiary hospitals in Nigeria sited in the south-south region of Nigeria.

2. **Study design**

   This was designed as a descriptive cross-sectional study structured to meet its primary aim and objectives which was conducted from October 2015 to June 2018.

3. **Ethical consideration**

   Ethical approval was obtained from the University of Port Harcourt Research Ethics Committee prior to the commencement of the study (approval number: UPTH/ADM/90/SII/VOLX/728). Informed consent was also obtained from each participant before recruitment. The entire study procedures were in accordance with the Declaration of Helsinki of 1964 and its recent revision in 2013.

4. **Sample size determination**

   The sample size was determined using the formula for sample size determination for the study of proportions in a population of greater than 10,000 using 15.7% PCa disease prevalence rate in Nigeria and a minimum sample size of 220 was obtained with 10% attrition included [4,16].

5. **Study population**

   The study population groups consisted of 220 PCa patients recruited from the Urology clinic of the hospital and 220 age-matched apparently healthy male control participants. The apparently healthy controls included were age-matched males who are devoid of any previous or current history and clinical features of any prostatic diseases with a total prostate-specific antigen (PSA) level of less than 4 ng/mL and normal digital rectal examination findings. PCa patients and controls excluded were non-consenting potential participants, those with history of previous prostatectomy for benign prostatic hyperplasia, those with medical history of other cancers.
those diagnosed with diabetes mellitus (since diabetes mellitus condition increases renal zinc excretion) and those with chronic renal diseases (since renal excretion of zinc increases in the polyuric phase of chronic renal diseases).

7. Sampling method
A simple random sampling technique was employed as a sampling method for the recruitment of the study participants.

8. Data acquisition
Middle-aged and elderly males who had presented in the Urology clinic following PCa diagnosis (via medical history interview, digital rectal examination, PSA test, and transperineal prostate biopsy confirmation) and the healthy controls were first assessed for inclusion and exclusion criteria after obtaining informed consent. Those who met the inclusion criteria were recruited following prostate biopsy by the urologist and subsequent histological confirmation by the histopathologists.

For each case selected, an age-matched (matched by ±3 years) male control was selected following medical history review, digital rectal examination and serum PSA test. Thereafter, questionnaires were administered to extract demographic variables and each participant was examined and their blood specimen was taken. Data obtained from each participant in both study groups were age (years), plasma zinc (µmol/L), fasting plasma glucose (mmol/L), plasma creatinine (µmol/L), serum total PSA (µg/L), calculated estimated glomerular filtration rate (mL/min) using the Modification of Diet in Renal Disease formula [17]. The ISUP grades were obtained from the prostate biopsy histological reports while cancer staging was done clinically at diagnosis prior to treatment using the guidelines recommended by the American Joint Committee on Cancer (AJCC) [18].

9. Specimen collection and laboratory analysis
Fasting venous blood specimen, collected from each participant every morning during the course of the study, was processed accordingly to obtain either the serum or plasma for laboratory analysis. Fasting plasma glucose was analyzed within 24 hours using the glucose oxidase method. Samples for creatinine and zinc were stored at -20°C and analyzed within 72 hours. Plasma creatinine was determined using the Jaffe kinetic method. The total serum PSA was determined using Enzyme-linked Immunosorbent assay method. The plasma zinc was determined via the flame atomic absorption spectrophotometry using the direct method described by Smith and associates [19]. Analytical procedures were monitored for accuracy and precision with the use of three levels of commercial quality control sera. The necessary precautions were taken to prevent environmental zinc contamination of blood samples, reagents, and equipment as recommended by the International Zinc Nutrition Consultative Group (IZiNCG) [20].

10. Data stratifications and definitions
The PCa disease grades were stratified based on the ISUP grading system [6]. Using the ISUP grades, PCa disease was arbitrarily categorized as mild-moderate grade (ISUP grade 1–3) or severe grade (ISUP grade 4–5) disease [6]. The AJCC clinical staging was also arbitrarily stratified at diagnosis prior to treatment as localized (clinical stage ≤cT2) or advanced (clinical stage ≥cT3) disease [18]. Zinc status was dichotomized as low (≤11.3 µmol/L) or normal (>11.3 µmol/L) based on the IZiNCG recommendations [20].

11. Statistical analysis of data
All the data acquired were keyed into the IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA) and were subsequently reviewed, validated and properly coded. The continuous variables were initially tested for normality of distribution using the Shapiro–Wilk test. All the observed non-parametric distributed data were subsequently logarithmically transformed prior to statistical analysis. The continuous variables were presented as mean±standard deviations and compared with the independent student t-test. The categorical variables were presented in numbers/percentages and compared with the chi-square test. Pearson’s correlation test was employed to examine the relationship between plasma zinc status and the ISUP grades. Binary logistic regression model was generated to determine the impact of low zinc status (plasma zinc ≤11.3 µmol/L) to predict severe grade and advanced PCa disease. Since plasma zinc status decreases with advancing age [20], age was also adjusted in the logistic regression models. An alpha value of <0.05 was chosen as being statistically significant.

RESULTS
This study was conducted between October 2015 and June 2018 at the UPTH. The study population consisted of 220 histologic confirmed PCa patients and 220 age-matched males with no evidence of prostate diseases.

Most of the study cohorts (n=152) had low zinc status compared to those with normal zinc status (n=68) based on the definition by the IZiNCG [20].
No statistical difference was observed in the age distribution of both study groups (p=0.291) since there were age-matched. However, there were statistical difference of the fasting plasma glucose (p<0.001), plasma creatinine (p<0.001), estimated glomerular filtration rate (p<0.001), total serum PSA (p<0.001) and plasma zinc levels (cases: 9.42±3.02 µmol/L versus controls: 15.23±4.47 µmol/L; p<0.001) among both study groups (Table 1).

The majority of the PCa patients presented with mild-moderate grade disease (n=137, 62.3%) while others (n=83, 37.7%) presented with severe grade disease (Table 2). Most of the patients had localized disease compared to those with advanced disease (localized: n=166, 75.5% versus advanced: n=54, 24.5%). The PCa patients with severe grade and advanced disease had significantly lower plasma zinc compared to those with the mild-moderate grade (p<0.001) and localized disease (p<0.001) respectively (Table 2).

Table 3 shows strong negative correlations between plasma zinc status and the ISUP grades among the overall PCa patients (r=-0.612, p<0.001) and among those with mild-moderate grade (r=-0.586, p<0.001), localized (r=-0.622, p<0.001) and advanced disease (r=-0.558, p<0.001). However, a moderate negative correlation was documented among those with severe grade disease (r=-0.408, p<0.001) as depicted (Table 3).

The impact of low zinc status to predict severe grade PCa disease was about 9-fold in crude (odds ratio [OR] 8.714; 95% confidence interval [CI], 3.746–20.273; p<0.001) regression model which was amplified to more than 11-fold in the age-adjusted (OR, 11.152; 95% CI, 4.467–27.843; p<0.001) model (Table 4). While the impact of low zinc status of predicting the advanced PCa disease was more than 17-fold in crude (OR, 17.160; 95% CI, 4.041–72.871; p<0.001) and amplified also to about 19-fold in the age-adjusted (OR, 18.927; 95% CI, 4.297–83.409; p<0.001) models respectively (Table 4).

### DISCUSSION

In this study, we had evaluated the impact of plasma zinc status on the severity (grade) and progression (stage) of PCa disease. One of the most significant findings of the study was the observed significant reduction of zinc status of the overall study population with PCa disease compared with the apparently healthy age-matched controls without evidence of prostatic diseases (cases: 9.42±3.02 µmol/L versus controls: 15.23±4.47 µmol/L; p<0.001). The low zinc status was more pronounced among those with severe grade and advanced stage of the disease with inverse relationship existing between the zinc status and the disease grade among the entire PCa patients and the other study subgroups. The mean plasma levels of zinc observed among the entire PCa patients and the patients with severe grade...
and advanced stage disease were below the normal cut-off value defined by the IZiNCG for adult males [20]. Low zinc status also had a significant odd of predicting severe grade and advanced stage PCa disease in crude and adjusted logistic regression models. These findings are in agreement with a number of recent reports which underscore the influence of zinc on the severity and progression of PCa disease.

A recent study reported from North India by Abhishek et al. [8] had noted decreased zinc status in PCa patients relative to controls (cases: 85±10.4 µg/L versus controls: 116±19.1 µg/L; p=0.001). A previous study reported in 2014 from South-eastern Nigeria had also observed similarly reduced plasma zinc in men with PCa disease compared to apparently healthy controls (cases: 22.5±6.4 µmol/L versus controls: 25.9±6.1 µmol/L; p<0.05) [9]. The reduction of the zinc status had consistently been documented from other regions of the world among PCa patients compared to controls [21-23]. However, Białkowska et al. [10] had recently reported a higher zinc status among Polish PCa patients compared to controls. While Eken et al. [11] found no difference in zinc status of Turkish PCa patients compared to controls. These reports [8,9] are at variance to our finding and could be related to environmental, dietary, genetic or study methodological differences. A recent meta-analysis by Gumulec et al. [22] had observed that the reduction of zinc status in PCa patients is an established fact in PCa disease. Though reports on the relationship between dietary zinc intake and PCa has produced inconsistent results due to the reliance on self-reported zinc intake, Mahmoud et al. [24] had recently reported lower zinc intake with increased PCa risk among African-Americans men.

A number of reports suggest a decreasing trend of prostatic tissue zinc status with increasing severity and progression of PCa disease [8,12]. Some other investigators had also evaluated the relationship between zinc status and prostate biopsy outcomes with encouraging results [25]. These reports are in accord with the findings of this present study. Cortesi et al. [12] had comprehensively evaluated this relationship and concluded that the reduction of zinc status in PCa tissues correlates with the grade of the PCa which determines the invasiveness and extension of the disease. This was recently corroborated by Abhishek and colleagues who documented a strong negative correlation between zinc status and tumor grade (r=-0.680, p=0.001) among Indian men with PCa disease [8].

Table 3. Correlation table of plasma zinc levels and ISUP grades among various subgroups

| Study subgroups                      | n  | r     | p-value |
|-------------------------------------|----|-------|---------|
| Overall prostate cancer patients    | 220| -0.612| <0.001* |
| PCa grade stratum                   |    |       |         |
| Mild-moderate grade disease (ISUP grade 1–3) | 137| -0.586| <0.001* |
| Severe grade disease (ISUP grade 4–5) | 83 | -0.408| <0.001* |
| PCa stage stratum                   |    |       |         |
| Localized disease (≤cT2)            | 166| -0.622| <0.001* |
| Advanced disease (≥cT3)             | 54 | -0.558| <0.001* |

ISUP, International Society of Urological Pathology; r, Pearson’s correlation coefficient; PCa, prostate cancer.
* Statistically significant (p<0.05).

Table 4. Result of binary logistics regression analysis of the impact of low plasma zinc status of predicting severe grade (ISUP grade 4–5) and advanced (≥cT3) PCa disease

|                  | B  | SE  | OR   | 95% CI     | p-value |
|------------------|----|-----|------|------------|---------|
| Severe grade disease |    |     |      |            |         |
| Normal zinc status (reference) | 1.0|      |      |            |         |
| Low zinc statusa  | 2.167| 0.432| 8.714| 3.746–20.273| <0.001c |
| Low zinc statusb  | 2.412| 0.467| 11.152| 4.467–27.843| <0.001c |
| Advanced stage disease |    |     |      |            |         |
| Normal zinc status (reference) | 1.0|      |      |            |         |
| Low zinc statusa  | 2.843| 0.738| 17.160| 4.041–72.871| <0.001c |
| Low zinc statusb  | 2.941| 0.757| 18.927| 4.297–83.409| <0.001c |

ISUP, International Society of Urological Pathology; PCa, prostate cancer; B, regression coefficient; SE, standard error; OR, odds ratio; CI, confidence interval.
*a: Model 1: crude. b: Model 2: age-adjusted. c: Statistically significant (p<0.05).
Cohort study found that long-term use of zinc supplements, although was not associated with reduced PCa risk, but was associated with reduced risk of advanced PCa disease [26].

However, a recent evaluation of the relationship between dietary zinc intake and the disease grade and stage by Gutiérrez-González et al. [27] did not support this association. Additionally, Park et al. [28] found no association between serum zinc status and PCa grade and stage.

The prostate gland has a high capacity of amassing high zinc concentrations from plasma with the aid of special transport proteins. The most important of these proteins is zinc transport protein 1 [22]. These proteins have the specialized ability to trap high amount of zinc from the extracellular plasma for the maintenance of the normal prostate gland physiology and biochemistry [14]. The intra-prostatic concentrations of zinc in the prostate gland also depends on the available quantities of plasma zinc concentrations [14,15]. The prostate zinc concentration has been reported with overwhelming evidence of inhibiting the promotion of carcinogenesis while enhancing various anti-cancer activities in the prostate gland. The reduction of zinc mineral in the prostate plasma and prostate tissue has been adjudged the most cardinal initiating event in prostate carcinogenesis [13]. Hence, the reduction of zinc status that occurs in these patients eliminates all the anticancer effects of zinc in the gland, enabling the malignant transformation of prostate cells, facilitating the malignant cells to meet the metabolic and bioenergetics of malignancy, enhancing their growth and progression to invade tissues and metastasize in the process [12-15].

The strength of this study lies in its prospective design and the recruitment of only the histologically-diagnosed PCa disease. However, there are some limitations that are worth mentioning. First, it was a hospital-based study conducted in a single center. Therefore, its findings might not be representative of the entire population in the region. Secondly, the Gleason grades were reported by different histopathologist, which is subject to inter- and intra-individual variations. Thirdly, prostate biopsy was not carried out on the controls due to ethical issues, so we cannot rule out with certainty that some of the controls did not harbor subclinical PCa. However, the controls were all healthy and ambulatory men with no medical history, clinical, and laboratory features of prostatic diseases. Finally, although plasma zinc is an accepted biomarker for zinc status owing to its response to zinc intakes and prediction of functional response to zinc supplementation, its plasma levels may not correlate well with zinc levels in prostate tissues [22,23].

**CONCLUSIONS**

The findings from this study support the epidemiologic evidence that zinc status is significantly reduced in patients with PCa compared to controls. The reduction was more pronounced among those with the severe grade and advanced stage PCa disease. Zinc status was found to be inversely associated with disease grades which tend to define the disease stage. This suggests that low zinc status influences the severity and progression of PCa disease. However, further elaborate and well-designed studies with large sample size are warranted to confirm these associations.

**CONFLICTS OF INTEREST**

The authors have nothing to disclose.

**REFERENCES**

1. Tao ZQ, Shi AM, Wang KX, Zhang WD. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci 2015;19:805-12.
2. Adeloye D, David RA, Aderemi AV, Iseolorunmami A, Oyedokun A, Iweala EE, et al. An estimate of the incidence of prostate cancer in Africa: a systematic review and meta-analysis. PLoS One 2016;11:e0153496.
3. Bowa K. An overview of the diagnosis and management of prostate cancer in Nigeria: experience from a north-central state of Nigeria. Ann Afr Med 2010;9:111-2.
4. Ukoli F, Osime U, Akereyeni F, Okunzuwa O, Kittles R, Adams-Campbell L. Prevalence of elevated serum prostate-specific antigen in rural Nigeria. Int J Urol 2003;10:315-22.
5. Ifere GO, Abebe F, Ananaba GA. Emergent trends in the reported incidence of prostate cancer in Nigeria. Clin Epidemiol 2012;4:19-32.
6. Egevad L, Delahunt B, Kristiansen G, Samaratunga H, Varma M. Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology 2018;50:60-73.
7. Epstein JJ, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the gleason score. Eur Urol 2016;69:428-35.
8. Abhishek A, Singh V, Sinha RJ, Ansari NG, Siddiqe MKJ, Verma M, et al. To study the relationship between cadmium, zinc and mtDNA copy number in North Indian patients suffering from prostate cancer: a case control study. Afr J Urol 2017;23:126-32.
9. Onyema-ilo BO, Meludu SC, Iloh E, Nnodim J, Onyegbule O, Mykembata B. Biochemical changes in some trace elements, antioxidant vitamins and their therapeutic importance in prostate cancer patients. Asian J Med Sci 2014;6:95-7.

10. Białkowska K, Marciniak W, Muszyńska M, Baszuk P, Gupta S, Jaworska-Bieniek K, et al. Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. PLoS One 2018;13:e0201065.

11. Eken A, Ünlü-Endirlik B, Kaya E, Özgök Y, Erdem O, Akay C. Evaluation of trace element levels in patients with prostate cancer, benign prostatic hyperplasia and chronic prostatitis. Gülhane Tip Derg 2016;58:27-32.

12. Cortesi M, Fridman E, Volkov A, Shilstein SSh, Chechik R, Breskin A, et al. New prospective for non-invasive detection, grading, size evaluation, and tumor location of prostate cancer. Prostate 2010;70:1701-8.

13. Zaichick VYe, Sviridova TV, Zaichick SV. Zinc in the human prostate gland: normal, hyperplastic and cancerous. Int Urol Nephrol 1997;29:565-74.

14. Costello LC, Feng P, Milon B, Tan M, Franklin RB. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis 2004;7:111-7.

15. Kolenko V, Teper E, Kutikov A, Uzzo R. Zinc and zinc transporters in prostate carcinogenesis. Nat Rev Urol 2013;10:219-26.

16. Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci 2006;1:9-14.

17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.

18. Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:245-53.

19. Smith JC Jr, Buttrimovitz GP, Purdy WC. Direct measurement of zinc in plasma by atomic absorption spectroscopy. Clin Chem 1979;25:1487-91.

20. International Zinc Nutrition Consultative Group (IZiNCG), Brown KH, Rivera JA, Bhutta Z, Gibson RS, King JC, et al. International Zinc Nutrition Consultative Group (IZiNCG) technical document #1. Assessment of the risk of zinc deficiency in populations and options for its control. Food Nutr Bull 2004;25(1 Suppl 2):S99-203.

21. Costello LC, Franklin RB, Feng P, Tan M, Bagasra O. Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States). Cancer Causes Control 2005;16:901-15.

22. Gumulec J, Masarik M, Adam V, Eckschlager T, Provaznik I, Kizek R. Serum and tissue zinc in epithelial malignancies: a meta-analysis. PLoS One 2014;9:e99790.

23. Zhao J, Wu Q, Hu X, Dong X, Wang L, Liu Q, et al. Comparative study of serum zinc concentrations in benign and malignant prostate disease: a systematic review and meta-analysis. Sci Rep 2016;6:25778.

24. Mahmoud AM, Al-Alem U, Dabbous F, Ali MM, Batai K, Shah E, et al. Zinc intake and risk of prostate cancer: case-control study and meta-analysis. PLoS One 2016;11:e0165956.

25. Temiz MZ, Cakir OO, Aykan S, Kucuk SH, Tiryakioğlu NO, Bilek G, et al. The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes. Biomark Med 2019;13:59-68.

26. Gonzalez A, Peters U, Lampe JW, White E. Zinc intake from supplements and diet and prostate cancer. Nutr Cancer 2009;61:206-15.

27. Gutiérrez-González E, Castelló A, Fernández-Navarro P, Castaño-Vinyals G, Llorca J, Salas D, et al. Dietary zinc and risk of prostate cancer in Spain: MCC-Spain study. Nutrients 2018;11:E18.

28. Park SY, Wilkens LR, Morris JS, Henderson BE, Kolonel LN. Serum zinc and prostate cancer risk in a nested case-control study: the multiethnic cohort. Prostate 2013;73:261-6.